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ORIGINAL ARTICLE
Overall and bleeding-related discontinuation rates of a new oral contraceptive
containing 4mg drospirenone only in a 24/4 regimen and comparison to
0.075mg desogestrel
Pedro-Antonio Regidora , Enrico Collib and Santiago Palaciosc
aExeltis Europe, Ismaning, Germany; bExeltis HealthCare Madrid, Madrid, Spain; cInstituto Palacios, Salud y Medicina de la Mujer, Madrid, Spain
ABSTRACT
Objectives: Progestin-only pills do not increase the risk of venous thromboembolism, stroke, and myocar-
dial infarction but are associated with poor cycle control. A novel estrogen-free pill containing only dro-
spirenone (DRSP) to improve bleeding patterns and tolerability and reduce discontinuation rates has
been introduced into the market. The present study aims to describe the improvement in the acceptabil-
ity of this DRSP-only pill, e.g. regarding the bleeding profile and the reduction in discontinuation rates
due to unacceptable bleeding compared to desogestrel (DSG).
Study design: Double-blind, double-dummy prospective phase III study in healthy women aged 18–45
years evaluating a total of 858 women with 6691 DRSP and 332 women with 2487 DSG treatment cycles.
Results: Overall, 82 (9.6%) women in the DRSP group and 44 (13.3%) women in the DSG group experi-
enced treatment-emergent adverse events (TEAEs) leading to premature termination of the trial meaning
that 32% more women in the DRSP group finished the trial in comparison to the DSG group (based on
the AUC of Kaplan–Meier’s curves). Discontinuation rates due to abnormal bleeding were 3.7% for DRSP
and 7.3% for DSG users. This is a 55.7% lower discontinuation rate in the DRSP group compared to the
DSG group.
Conclusions: This report describes the improvement in acceptability and bleeding profile of women
using the new DRSP-only oral contraceptive compared to DSG, providing a better quality of life and
adherence to the contraceptive method as demonstrated by lower discontinuation rates of women using
the estrogen-free DRSP-only pill.
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Shortly after introducing the first combined oral contraceptives
(COCs) in the 1950s, researchers described the first cases of deep
venous thromboembolism (VTE) under this contraceptive
method [1]. Since the estrogen component of the COCs (ethiny-
lestradiol) was primarily blamed as a possible cause of the onset
of thrombosis, and due to other estrogen-related side effects
such as weight gain, bleeding disorders, nausea, and bloating, a
reduction in the dosage of the estrogens was continuously intro-
duced in the 1970s. The decrease in the estrogen dose of the
COCs correlated with a reduced risk of VTE events [2–4].
Efforts to further reduce the risk have also changed the pro-
gestin component over time. After introducing the first COCs
(which included the progestins lynestrenol, and ethynodiol diace-
tate), new progestins like levonorgestrel were introduced in the
1970s, and gestodene and desogestrel (DSG) in the 1980s.
The next generation of progestins, such as DSG, gestodene,
and drospirenone (DRSP), bind more specifically to the proges-
terone receptor and show a reduction in androgenic, estrogenic,
and glucocorticoid-related side effects, with a more neutral
impact on metabolic parameters [5]. Unfortunately, these new
progestogens used in combination with ethinylestradiol have
been associated with an increase in VTE risk in comparison to
COC with levonorgestrel [6]. Therefore, the use of estrogen-free
progestogens is increasing because of their cardiovascular
safety profile.
All EU countries, the US Food and Drug Administration, and
other agencies worldwide have recently approved a novel estro-
gen-free contraceptive with DRSP 4mg [7,8].
For long, the problematic bleeding while using progestin-only
pills (POPs) was challenging [9]. During a normal menstrual
cycle, the endometrium is exposed to circulating sex steroids.
The sequential exposure of the endometrium to natural steroids,
estradiol, and progesterone leads to characteristic histological fea-
tures [10].
The mechanisms involved in bleeding-associated disorders
during the use of combined hormonal contraceptives or estro-
gen-free contraceptives are still unclear. Together with a superfi-
cial blood vessel permeability and the steroid hormone-induced
change of endometrium receptors, local angiogenetic factors are
the most accepted explanation for these bleeding disor-
ders [11,12].
Women using contraceptives associate the occurrence of
unscheduled bleeding or spotting negatively. Problematic bleed-
ing is the most common quoted reason for user discontinuation
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in up to 25% of users [13,14]. The objective of this study was to
assess the effect of DRSP 4mg vs. DSG 0.075mg on the discon-




This phase III study was a double-blinded, double-dummy,
randomized controlled trial including 88 centers in Austria,
Czech Republic, Germany, Hungary, Poland, Romania, Slovakia,
and Spain
Ethics approval
The protocol was designed, and the study conducted according
to existing legal regulations and following Good Clinical Practice
in clinical trials and the Declaration of Helsinki, including
recommendations in the European Medicines Agency Committee
for Medicinal Products for Human Use Guideline on Clinical
Investigation of Steroid Contraceptives in Women. Institutional
review board approval was obtained for all study sites. All partic-
ipants gave their written informed consent for participation in
the clinical trial after obtention of the correspondent ethics com-
mittee approval for each of the investigational centers The over-
all approval for the trial was given in July 2012 by the leading
ethics committee (Landesamt f€ur Gesundheit und Soziales Berlin,
Gesch€aftstelle der Ethik Kommission des Landes Berlin, number
11/0606 EK) (EudraCT 2011-002396-42). The study was per-
formed between August 2012 and January 2014.
Study medication
The study medication was DRSP, one tablet of 4mg non-micron-
ized DRSP per day, via the oral route, with consecutive adminis-
tration of 24 active pills and four placebo tablets with no tablet-
free interval between two successive cycles (24/4 regimen).
Assessed for eligibility (n=1365) 
Analyzed (n=858) 
 Excluded from analysis (n=0)
Lost to follow-up (n=0) 
Discontinued intervention (n=170) (57 at 
patients request, 5 major protocol violations, 4 
pregnancies, 4 wish for pregnancy, 5 ineligible, 
82 adverse events, 13 other) 
Allocated to DRSP (n=872) 
 Received allocated intervention (n=858)
 Did not receive allocated intervention (n=14) 
(8 withdrew consent, 1 investigator’s 
opinion, 2 pregnancies, 2 ineligible, 
1 other)
Lost to follow-up (n=0) 
Discontinued intervention (n=83) (28 at 
patients request, 3 major protocol violations, 1 
pregnancy, 1 wish for pregnancy, 3 ineligible, 
44 adverse events, 3 other) 
Allocated to DSG (n=341) 
 Received allocated intervention (n=332)
 Did not receive allocated intervention (n=8) 
(6 withdrew consent, 1 adverse event, 
1 other)
Analyzed (n=332) 






Figure 1. CONSORT diagram.
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The comparator was DSG 0.075mg in a regimen of 28 active
pills, marketed under trade names such as CerazetteVR and
CerazetVR , as it also inhibits ovulation as a POP. It is also the first
POP with a missed pill window of 12 h, instead of the 3 h
allowed by conventional POPs, and is one of the leading POPs
on the European market.
We assessed medication compliance using an electronic diary,
providing time and hour of each tablet intake, allowing for cal-
culation of the number of study medication delayed tablet intake
for more than 12 h, i.e. more than 36 h after the last tab-
let intake.
Study population
A total of 858 women with 6691 DRSP and 332 women with
2487 DSG treatment cycles were analyzed. Women included in
this study were all of child-bearing potential, at risk of preg-
nancy, agreeing to use only the study medication for contracep-
tion for the duration of the study treatment, aged 18–45, with
systolic blood pressure <140mmHg and diastolic blood pres-
sure <90mmHg.
The medication groups were divided into starter¼ first
administration of a hormonal contraceptive or at least 4-month
break after the administration of another hormonal contraceptive
or switcher¼ direct switch from another hormonal contraceptive
to the studied drug with no gap in administration.
Sample size
To test non-inferiority of the discontinuation parameters
between the two treatment groups (assuming a 24% proportion
of the control group, a 9% non-inferiority margin, a one-sided
type I error 2.5, 80% power, and a 2:1 treatment allocation rate),
a sample size of 531 in the DRSP group and 266 in the DSG
group was required. A sample size of 443 women in the DRSP
group and 222 in the DSG group was needed to prove superior-
ity under the same assumptions. Considering the possibility of a
drop-out rate of 20%, 857 DRSP- and 333 DSG-treated women
were to be enrolled in the clinical trial.
Randomization and blinding
Randomization was performed using a validated system that
automates the random assignment of treatment groups to ran-
domization numbers. The randomization scheme was completed
in a 5:2 ratio using blocking methodology via a center-based ran-
domization method. The randomization data were kept strictly
confidential, accessible only at the time of unblinding. The
DRSP-only group received the test product (DRSP 4.0mg) in
blister A plus reference placebo in blister B. The DSG group
received the test placebo in blister A plus reference product
(DSG 0.075mg) in blister B.
Safety analysis
Safety analyses were performed for the Safety Set. Safety assess-
ments were to be summarized by treatment groups by means of
the default summary statistics. All treatment-emergent adverse
events (TEAEs) were summarized by calculating the number and
percentage of women with adverse events by preferred term and
system organ class. TEAEs were also summarized by severity and
relationship to treatment. The number and percentage of women
with serious adverse events and TEAEs leading to premature dis-
continuation were provided.
Statistics
The discontinuation rate statistic was performed on the Full Analysis
Set bleeding data and was summarized by treatment groups using
summary statistics. A chi-square test was applied to compare rates
in both treatment groups. AUC estimates were calculated for both
analyzed discontinuation rates (overall and bleeding related).
Results
Study population
A total of 1213 women were randomized to DRSP (872 women)
or DSG (341 women), and 1190 received the allocated treatments
(858 DRSP and 332 DSG, see Figure 1). Of 1190 treated women,
253 (21.2%) women terminated prematurely: 170 women (19.8%)
in the DRSP group and 83 women (24.9%) in the DSG group
(see Figure 1 and Table 1).
Analysis of adverse events
Overall, 15.7% of women in the DRSP group and 18.7% of
women in the DSG group experienced TEAEs classified as at
least possibly related to the study treatment. The most frequently
reported TEAEs assessed as possibly related to the trial treatment
were vaginal bleeding (3.1% in the DRSP group and 6.0% in the
DSG group, p< .05), acne (3.0% DRSP and 5.1% DSG), and
weight increased (2.2% DRSP and 1.8% DSG).
The frequency of individual TEAEs assessed as severe was
low. Four of them were related to vaginal bleeding (two women
per treatment group, i.e. 0.2% in the DRSP group and 0.6% in
the DSG group) and two women (0.2%) in the DRSP and one






Age (years) Mean (SD) 28.9 (7.1) 28.9 (7.1)
Age group
35 years n (%) 682 (79.5) 259 (78.0)
>35 years n (%) 176 (20.5) 73 (22.0)
Ethnicity
Caucasian n (%) 856 (99.8) 331 (99.7)
BMI (kg/m2) Mean (SD) 22.96 (3.537) 22.82 (3.905)
Min/max 16.6/41.0 15.9/38.0
BMI group
<30 kg/m2 n (%) 828 (96.5) 316 (95.2)
30 kg/m2 n (%) 30 (3.5) 16 (4.8)
Blood pressure group
SBP <130 and DBP <85mmHg n (%) 727 (84.7) 290 (87.3)
SBP 130 and DBP 85mmHg n (%) 131 (15.3) 42 (12.7)
Subject status
Switcher n (%)
Direct switcher n (%) 628 (73.2) 259 (78.0)
Indirect switcher n (%) 39 (4.5) 14 (4.2)
Starter n (%) 191 (22.3) 59 (17.8)
Unknown n (%) – –
VTE risk factors
Presence of at least one risk factor n (%) 142 (16.5) 59 (17.8)
Previous delivery
Yes n (%) 395 (46.0) 150 (45.2)
Regular menstrual bleeding during the last 6 cycles
Yes n (%) 786 (91.6) 305 (91.9)
Prior treatment with sex hormones and modulators of the genital system
Yes n (%) 469 (54.7) 195 (58.7)
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Table 2. Incidence of TEAEs leading to premature discontinuation.
DRSP (N¼ 858) DSG (N¼ 332) Total (N¼ 1190)
Preferred term n (%) n (%) n (%)
Subjects with at least one TEAE leading to premature discontinuation 82 (9.6) 44 (13.3) 126 (10.6)
Abnormal uterine bleeding 27 (3.5) 22 (6.9) 49 (4.2)
Acne 9 (1.0) 9 (2.7) 18 (1.5)
Weight increased 8 (0.9) 3 (0.9) 11 (0.9)
Libido decreased 5 (0.6) 2 (0.6) 7 (0.6)
Headache 2 (0.2) 2 (0.6) 4 (0.3)
Alopecia 2 (0.2) 1 (0.3) 3 (0.3)
Mood swings 3 (0.3) 0 3 (0.3)
Abdominal pain 2 (0.2) 0 2 (0.2)
Depressed mood 2 (0.2) 0 2 (0.2)
Depression 1 (0.1) 1 (0.3) 2 (0.2)
Gamma-glutamyltransferase increased 2 (0.2) 0 2 (0.2)
Nausea 2 (0.2) 0 2 (0.2)
Rash 2 (0.2) 0 2 (0.2)
Abdominal pain lower 1 (0.1) 0 1 (0.1)
Abdominal pain upper 1 (0.1) 0 1 (0.1)
Affective disorder 1 (0.1) 0 1 (0.1)
Alanine aminotransferase increased 1 (0.1) 0 1 (0.1)
Blood thyroid stimulating hormone increased 1 (0.1) 0 1 (0.1)
Constipation 1 (0.1) 0 1 (0.1)
Contact lens intolerance 1 (0.1) 0 1 (0.1)
Dysmenorrhea 1 (0.1) 0 1 (0.1)
Feeling abnormal 0 1 (0.3) 1 (0.1)
Generalized edema 0 1 (0.3) 1 (0.1)
Hot flush 1 (0.1) 0 1 (0.1)
Hyperhidrosis 1 (0.1) 0 1 (0.1)
Hyperthyroidism 1 (0.1) 0 1 (0.1)
Hypertrichosis 0 1 (0.3) 1 (0.1)
Malaise 1 (0.1) 0 1 (0.1)
Premenstrual syndrome 1 (0.1) 0 1 (0.1)
Respiratory tract infection 1 (0.1) 0 1 (0.1)
Skin disorder 0 1 (0.3) 1 (0.1)
Vertigo 1 (0.1) 0 1 (0.1)




































0 1 2 3 4 5 6 7 8 9
Duration of contraceptive use (months)
Arm Treatment duration (months) AUC
DSG 9 0.8566588
DRSP 9 0.583116
Figure 2. Probability of discontinuation due to adverse events. Kaplan–Meier’s curve. DSG: desogestrel; DRSP: drospirenone; AUC: area under the curve.
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(0.3%) in the DSG group experience acne and libido decrease,
respectively. Headache was reported by two women (0.2%) in the
DRSP group. All other severe TEAEs each occurred only in
one woman.
Adverse events leading to study discontinuation
Overall, 82 (9.6%) women in the DRSP group and 44 (13.3%)
women in the DSG group experienced TEAEs leading to study
discontinuation (see Table 2). The most common individual
TEAEs leading to withdrawal were vaginal bleeding (2.6% in the
DRSP group vs. 5.4% in the DSG group) and acne (1.0% in the
DRSP group vs. 2.7% in the DSG group).
Using the Kaplan–Meier curve estimates and the area under
the curve (AUC) for the overall adverse events as a discontinu-
ation reason, the difference between DRSP and DSG was 32.0%
in favor of DRSP, with AUC estimates of 0.583 for DRSP and
0.857 for DSG (see Figure 2). The discontinuation rate was 10%
for the DRSP group and 14% for the DSG group (p< .005).
In total, 48 (5.5%) women in the DRSP group and 33 (9.9%)
in the DSG group experienced bleeding-related TEAEs (see
Table 3). Most of the bleeding-related TEAEs were mild or mod-
erate, whereas four (0.4%) women with DRSP and three (0.9%)
women with DSG experienced TEAEs of severe intensity. A total
of 28 (3.3%) women in the DRSP group and 22 (6.6%) women
in the DSG group discontinued the trial due to bleeding-related
TEAEs (p< .005).
Using the Kaplan–Meier curve estimates and the AUC for
bleeding as a discontinuation reason, the difference between
DRSP and DSG was 55.7% in favor of DRSP, with AUC esti-
mates of 0.199 for the DRSP group and 0.449 for the DSG group
(see Figure 3). The discontinuation rate was 3.7% for the DRSP
group and 7.3% for the DSG group.
Discussion
Increasing satisfaction with contraception is essential to help
women feel comfortable with the method and continue its use.
The most common reason for stopping a contraceptive method
completely due to dissatisfaction is the bleeding profile. As
described by Hooper [15], the side-effect profile of a contracep-
tive is another important determinant governing selection, as
Table 3. TEAEs related to bleeding disorders in total and by relatedness, severity, and discontinuation.
DRSP (N¼ 858) DSG (N¼ 332)
Total Related Severe Discontinuation Total Related Severe Discontinuation
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Abnormal uterine bleeding 40 (4.6) 35 (4) 3 (0.3) 27 (3.2) 31 (9.3) 27 (8.1) 2 (0.6) 22 (6.6)
Dysmenorrhea 8 (0.9) 5 (0.6) 1 (0.1) 1 (0.1) 2 (0.6) 1 (0.3) 1 (0.3) 0
Total 48 (5.5) 40 (4.6) 4 (0.4) 28 (3.3) 33 (9.9) 28 (8.4) 3 (0.9) 22 (6.6)
DRSP: drospirenone; DSG: desogestrel; TEAE: treatment-emergent adverse event.
Desogestrel
Drospirenone









































0 1 2 3 4 5 6 7 8 9
Duration of contraceptive use (months)
Figure 3. Probability of discontinuation due to adverse events of bleeding. Kaplan–Meier’s curve. DSG: desogestrel; DRSP: drospirenone; AUC: area under the curve.
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this may negatively influence compliance and persistence with
the prescribed regimen [16–19].
Our approach to investigate the discontinuation rates due to
bleeding is also in accordance with the findings by Hooper [15]
who could show that women (especially those in the older age
groups) are willing to compromise between effects on the men-
strual cycle and other contraceptive attributes when selecting the
method that is right for them. More than 40% of participants of
the above-mentioned survey indicated that they would consider
using a highly effective contraceptive even if it might cause
bleeding irregularities, and over 50% documented their wish to
accept irregular bleeding if they could have fewer or no periods
over the time. Nevertheless, the reasons given for asking for a
switch from one hormonal contraceptive to another indicate that
bleeding/spotting issues and other contraceptive-related side
effects remain a potential barrier to the continuance of the use
of such methods [15].
The trend of using estrogen-free contraceptives, despite the
possible occurrence of bleeding irregularities, is also triggered by
an improved cardiovascular safety of POPs even in comparison
to the use of low-dose second-generation COCs [6].
It is worth noting that the discontinuation rates for DRSP as
a POP in this study are comparable to reported discontinuation
rates of COCs containing 20 and 30 mg ethinylestradiol (findings
of the study of Edelman are presented in Figure 4) [20]. This
indicates that the new generation of estrogen-free contraceptives
does not expose women to a significantly higher probability of
discontinuation when compared to COCs.
Adding to this general consideration, associated factors like
overweight/obesity, age >35, and smoking result in additive car-
diovascular risks [21]. Therefore, the use of estrogen-free formu-
lations like the DRSP-only pill will gain a higher relevance.
Hence, the improvement in the acceptability of the bleeding
profile of the new POP with DRSP alone will help to increase
the use of POPs in all groups of women.
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